السويد - السويدية - Läkemedelsverket (Medical Products Agency)

sanofi ab - enoxaparinnatrium - injektionsvätska, lösning i förfylld spruta - 10 000 ie (100 mg)/1 ml - enoxaparinnatrium 100 mg aktiv substans

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

sanofi ab - enoxaparinnatrium - injektionsvätska, lösning i förfylld spruta - 8 000 ie (80 mg)/0,8 ml - enoxaparinnatrium 80 mg aktiv substans

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

2care4 aps - dorzolamidhydroklorid; timololmaleat - Ögondroppar, lösning - 20 mg/ml + 5 mg/ml - mannitol hjälpämne; timololmaleat 6,83 mg aktiv substans; dorzolamidhydroklorid 22,26 mg aktiv substans; bensalkoniumklorid hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

2care4 aps - dorzolamidhydroklorid; timololmaleat - Ögondroppar, lösning - 20 mg/ml + 5 mg/ml - mannitol hjälpämne; timololmaleat 6,83 mg aktiv substans; dorzolamidhydroklorid 22,26 mg aktiv substans; bensalkoniumklorid hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - dorzolamidhydroklorid; timololmaleat - Ögondroppar, lösning - 20 mg/ml + 5 mg/ml - bensalkoniumklorid hjälpämne; mannitol hjälpämne; timololmaleat 6,83 mg aktiv substans; dorzolamidhydroklorid 22,26 mg aktiv substans

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

sanofi ab - enoxaparinnatrium - injektionsvätska, lösning i förfylld spruta - 150 mg/ml - enoxaparinnatrium 150 mg aktiv substans - enoxaparin

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

actavis group ptc ehf - topotekan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastiska medel - topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5. topotecan i kombination med cisplatin är indicerat för patienter med cancer i livmoderhalsen återkommande efter strålbehandling för patienter med stadium ivb sjukdom. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

dendreon uk ltd - autologa perifera blodmononukleära celler innefattande minst 50 miljoner autologa cd54 + -celler aktiverade med prostatisk syrafosfatasgranulocyt-makrofagkolonistimulerande faktor - prostatiska neoplasmer - andra immunostimulanter - provenge är indicerat för behandling av asymptomatisk eller minimalt symptomatisk metastatisk (icke-visceral) castratresistent prostatacancer hos manliga vuxna, i vilka kemoterapi ännu inte är kliniskt indikerad.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-cell - antineoplastiska medel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.